Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

CeriBell, Inc. (CBLL) SEC Filings & Earnings Calls

EquiReason read 15 CeriBell, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-10 — Quarterly report filed with updated financials; no earnings beat or miss stated..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CBLLCeriBell, Inc.Follow CBLL — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
1.0B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
3 Nov, in 10 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

10 Aug 202610-QQuarterly report filed with updated financials; no earnings beat or miss stated.earningsopen

Figures in the filing · each found in the filing text

Net loss · H1-2026$-39M
Accumulated deficit · 2026-06-30$259M

Risks flagged

Single product dependency

“We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.” · word for word

Customer termination risk

“Existing customers may choose to terminate or not renew their subscription typically on 30 days’ notice to us without payment of a penalty or termination fee” · word for word

Algorithm performance risk

“Villamar et al. (2023) ... found that the Clarity algorithm ... did not detect seizures in the four patients who were experiencing them.” · word for word

Tariff and supply chain risk

“We rely on manufacturing facilities and third-party suppliers outside the United States, including in China and Vietnam, for the primary assembly and inspection of our Wearables and for a significant portion of our components.” · word for word

Reimbursement risk

“If adequate reimbursement becomes unavailable for the diagnostic tests using our products, it could diminish our sales or affect our ability to sell the Ceribell System profitably.” · word for word
Read the original on SEC EDGAR ↗
10 Aug 20268-K · 2.02Total revenue $28M (+33% y/y); Product revenue $21M (+33% y/y); Subscription revenue $7M (+30% y/y); Guidance: Revenue guidance raised to $114-117M from prior rangeearningsopen

Figures in the filing · each found in the filing text

Total revenue · Q2-2026$28M+33% y/y
Product revenue · Product · Q2-2026$21M+33% y/y
Subscription revenue · Subscription · Q2-2026$7M+30% y/y
Gross margin · Q2-202692.0%
Active accounts · Q2-2026712
Net loss · Q2-2026$-19M+42% y/y
Adjusted EBITDA loss · Q2-2026$-10M-2% y/y
Cash, cash equivalents, and marketable securities · Q2-2026$129M

Guidance

Revenue guidance raised to $114-117M from prior range

Revenue guidance raised; strong demand and margin expansion.

Risks flagged

Net loss widening; operating expenses growing faster than revenue.

“Net loss $19.3M vs $13.6M; operating expenses +37%.”
Read the original on SEC EDGAR ↗
30 Jul 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)SEC ↗
11 May 20268-K · 2.02Total revenue $26M (+29% y/y); Product revenue $20M (+29% y/y); Subscription revenue $6M (+29% y/y); Guidance: FY2026 revenue guidance raised to $112M-$116M (26-30% growth)earningsopen

Figures in the filing · each found in the filing text

Total revenue · Q1-2026$27M+29% y/y
Product revenue · Q1-2026$20M+29% y/y
Subscription revenue · Q1-2026$6M+29% y/y
Gross margin · Q1-202687.0%
Active accounts · Q1-2026680
Net loss · Q1-2026$-20M+54% y/y
Adjusted EBITDA loss · Q1-2026$-11M+3% y/y
Cash, cash equivalents, and marketable securities · Q1-2026$141M

Guidance

FY2026 revenue guidance raised to $112M-$116M (26-30% growth)

Ceribell raised FY2026 revenue guidance reflecting strong demand and execution.

Risks flagged

Increasing net loss and operating expenses, including legal costs from patent litigation, may pressure cash runway.

“Net loss increased to $19.7M from $12.8M; operating expenses rose 36% to $43.9M, partly due to legal costs for patent infringement suit.”

Dependence on third-party manufacturers in China and Vietnam introduces supply chain risk.

“Risk factors mention reliance on third-party manufacturers and suppliers in China and Vietnam.”
Read the original on SEC EDGAR ↗
11 May 202610-QNet Loss $-20M; Accumulated Deficit $-240Mopen

Figures in the filing · each found in the filing text

Net Loss · Q1-2026$-20M
Accumulated Deficit · 2026-03-31$-240M

Risks flagged

Tariff and Supply Chain Risk

“We rely on manufacturing facilities and third-party suppliers outside the United States, including in China and Vietnam, for the primary assembly and inspection of our Wearables and for a significant portion of our components.” · word for word

Reimbursement Risk

“In August 2023, CMS approved an NTAP under the Medicare inpatient prospective payment system for our newest Clarity algorithm, effective October 1, 2023. The NTAP designation for a product lasts for no more than three years for a specific indication.” · word for word

Product Liability Risk

“The production and sale of defective products could adversely affect our business, financial condition, results of operations, and prospects.” · word for word
Read the original on SEC EDGAR ↗
20 Apr 2026DEF 14AAnnual proxy statement filed for 2026 shareholder meeting; no material event.SEC ↗
24 Feb 202610-KNet Loss $-53M; Accumulated Deficit $-220Mopen

Figures in the filing · each found in the filing text

Net Loss · FY2025$-53M
Accumulated Deficit · FY2025$-220M

Risks flagged

History of net losses and expected continued losses

“We have incurred net losses since inception, and we expect to incur additional substantial losses in the foreseeable future.” · word for word

Tariff and supply chain risk

“Tariffs on products imported from China could adversely affect our suppliers’ operations, potentially causing disruptions or requiring us to transition to alternative manufacturers.” · word for word
Read the original on SEC EDGAR ↗
24 Feb 20268-K · 2.02Total Revenue $89M (+36% y/y); Product Revenue $67M (+34% y/y); Subscription Revenue $22M (+41% y/y); Guidance: 2026 revenue $111M-$115M (25-29% growth)earningsopen

Figures in the filing · each found in the filing text

Total Revenue · FY2025$89M+36% y/y
Product Revenue · FY2025$67M+34% y/y
Subscription Revenue · FY2025$22M+41% y/y
Gross Margin · FY202588.0%
Active Accounts · Q4-2025647
Net Loss · FY2025$-53M+32% y/y

Guidance

2026 revenue $111M-$115M (25-29% growth)

Strong growth trajectory with continued momentum expected

Risks flagged

Net losses continue despite strong revenue growth

“Net loss of $53.4 million in 2025, up from $40.5 million in 2024”

Operating expenses growing faster than revenue

“Operating expenses increased 42% vs revenue growth of 36%”
Read the original on SEC EDGAR ↗
5 Jan 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen

Risks flagged

No new risk signals; regulatory designation is positive.

Read the original on SEC EDGAR ↗
2 Jan 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen

Risks flagged

No material risk; routine board change.

Read the original on SEC EDGAR ↗
12 Dec 20258-K · 1.01Entered a material definitive agreement (acquisition, partnership, or major contract); filed financial statements and exhibits with this reportSEC ↗
9 Dec 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportSEC ↗
24 Nov 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportSEC ↗
4 Nov 20258-K · 2.02Total revenue $23M (+31% y/y); Product revenue $17M (+28% y/y); Subscription revenue $6M (+44% y/y); Guidance: FY2025 revenue guidance raised to $87-89M from prior rangeearningsopen

Figures in the filing · each found in the filing text

Total revenue · Q3-2025$23M+31% y/y
Product revenue · Product · Q3-2025$17M+28% y/y
Subscription revenue · Subscription · Q3-2025$6M+44% y/y
Gross margin · Q3-202588.0%
Net loss · Q3-2025$-14M
Total active accounts · Q3-2025615
Cash, cash equivalents, and marketable securities · Q3-2025$169M

Guidance

FY2025 revenue guidance raised to $87-89M from prior range

Raised full-year revenue guidance reflecting strong commercial execution and adoption

Risks flagged

Operating expenses growing faster than revenue (39% vs 31%), leading to net loss

“Operating expenses increased 39% to $34.6 million, while revenue grew 31%”

Dependence on China/Vietnam manufacturing and tariff exposure

“Manufacturing of a substantial number of our product components and their assembly in China and Vietnam” · word for word
Read the original on SEC EDGAR ↗
4 Nov 202510-QCeriBell reported Q3 2025 results with 31% revenue growth, improved gross margins, but increased net loss due to higher operating expenses.earningsopen

Figures in the filing · each found in the filing text

Total revenue · Q3-2025$23M+31% y/y
Product revenue · Q3-2025$17M+28% y/y
Subscription revenue · Q3-2025$6M+44% y/y
Gross margin · Q3-202588.0%
Net loss · Q3-2025$-13M+29% y/y
Active accounts · Q3-2025600

Risks flagged

Patent infringement litigation

“General and administrative expenses increased due to costs associated with intellectual property enforcement activities, including a new patent infringement claim initiated in July 2025.”

Continued operating losses

“We have incurred operating losses since the commencement of our operations and we expect to continue to incur losses as we grow and continue the transition to operating as a public company.” · word for word

Dependence on new account acquisition and utilization

“Our revenue fluctuates primarily based on the number of active accounts and the volume of headband usage.” · word for word
Read the original on SEC EDGAR ↗

CeriBell, Inc. — questions

What did CeriBell, Inc. file recently?
15 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-10 — Quarterly report filed with updated financials; no earnings beat or miss stated.

Every figure on this page comes from CeriBell, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.